Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VELOTA: JNJ-88545223 in Active Psoriatic Arthritis
jRCT2031250700Phase 2Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2026
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of JNJ-88545223 in psoriatic arthritis (PsA) and plaque psoriasis (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: ACR50 response at Week 16. Started Apr 2026; status: recruiting.
02
Drugs
JNJ-88545223
03
Conditions
psoriatic arthritis (PsA)plaque psoriasis
Beyond the preview
Go deeper on jRCT2031250700.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250700.